RESPONSE GENETICS............ buran und MfG  

Berliner LIVE Lampe:::::: ::::::::::­:::::: 1,47 € +0,48% +0,007 € ,GrB
 

24er Tickerwand im Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
24.10.13 2,07 2,15 2,01  2,09 $ 16.077 32.607

GrB  

die aktuellen Preis Angebote Berlin 1,557  Nasda­q 2,14 $  buran­ und MfG und tau
 

you like that ..::oohooooo ..::OOHYEAaaaaa Zeit  Kurs  Stück­  
20:20:56 2,08 $  100  
20:08:22 2,08 $  100  
19:59:28 2,08 $  100  
19:59:25 2,07 $  100  
19:59:25 2,0799 $  1.500­  
19:59:25 2,08 $  1.500­  
19:57:42 2,08 $  1.400­  
19:57:41 2,08 $  100  
19:57:11 2,07 $  650  
19:17:35 2,08 $  200  
19:17:35 2,09 $  300  
19:17:35 2,07 $  100  
19:17:35 2,09 $  300  
17:31:24 2,0801 $  1.900­  
17:31:24 2,08 $  100  
17:30:52 2,091 $  2.500­  
16:40:01 2,06 $  400  
16:40:01 2,061 $  1.600­  
16:27:21 2,041 $  300  
16:20:59 2,031 $  100  
16:20:59 2,04 $  100

Kosmonova buran  

relaxe take your time Zeit
  Kurs  Stück­ §
 21:00­:00§2,04 $
  318 §
 20:59­:54§2,04 $
  100 §
 20:59­:53§2,01 $
  100 §
 20:55­:06§2,0111­ $
  100 §
 20:50­:34§2,03 $
  600 §
 20:50­:13§2,02 $
 §1.00­0
 20:50­:07§2,021 $
  1.100­ §
 20:50­:07§2,02 $
  100 §
 20:50­:07§2,021 $
  100 §
 20:50­:06§2,02 $
  1.300­ §
 20:39­:16§2,03 $
  200 §
 20:39­:14§2,04 $
  100 §
 20:20­:59§2,0375­ $
  100 §
 19:53­:01§2,05 $
  3.280­ §
 19:48­:07§2,05 $
  800 §
 19:07­:28§2,055 $
  300 §
 19:07­:14§2,05 $
  300 §
 18:11­:01§2,05 $
  100 §
 18:11­:00§2,05 $
  5.743­ §
 18:10­:49§2,0501­ $
  1.992­ §
 18:08­:28§2,06 $
  100 §
 18:08­:21§2,06 $
  100 §
 18:07­:35§2,10 $
  500 §
 17:53­:09§2,05 $
  100 §
 17:52­:14§2,05 $
  200 §
 17:52­:00§2,05 $
  100 §
 17:51­:20§2,05 $
  200 §
 17:48­:45§2,079 $
  2.000­ §
 17:02­:17§2,05 $
  300 §
 17:01­:38§2,05 $
  3.010­ §
 16:59­:44§2,05 $
  100 §
 16:42­:12§2,06 $
  100 §
 16:40­:58§2,06 $
  200 §
 16:40­:29§2,07 $
  1.000­ §
 16:35­:10§2,07 $
  200 §
 16:26­:28§2,06 $
  100 §
 16:15­:25§2,07 $
  1.000­ §
 15:53­:51§2,07 $
  100 §
 15:44­:29§2,13 $
  300 §
 15:15­:03§2,0502­ $
  250 §
 15:15­:03§2,0501­ $
 200§
buran  

wir arbeiten Zeit  Kurs  Stück­  
15:22:24 2,0101 $  250  
15:19:00 2,0101 $  2.000­  
14:48:47 2,02 $  1.000­  
14:35:00 2,02 $  100

GrB  

RGDX realtime::::::: ::::::::::­::::: 2,05 $ +0,49% +0,01 $ In Euro: 1,5201 € | Nasdaq ,GrB  

wild boys ::::::::::­::: 2,11 $ +3,43% +0,07 $ In Euro: 1,5641 € | Nasdaq, 01.11.13 ,GrB  

activ Zeit
  Kurs  Stück­ §
 15:58­:21§2,20 $
  100 §
 15:50­:08§2,20 $
  100 §
 15:47­:24§2,149 $
  250 §
 15:47­:24§2,15 $
  500 §
 15:47­:23§2,149 $
  500 §
 15:47­:22§2,18 $
  100 §
 15:31­:43§2,1499­ $
  475 §
 15:30­:00§2,14 $
 300§
GrB  

04er Tickerschluss Lampe:::::: ::::::::::­::::: 2,14 $ +1,42% +0,03 $ In Euro: 1,5855 € | Nasdaq, 04.11.13 ,GrB  

thread update RTK 1,546 € RTP +1,38 Pott +5,17% ,GrB  

575 Nasdaq 575 Zeit   Kurs Stück
 15:30­:12§2,0392­ $ 475
 15:30­:00§2,17 $ 100
__________­_________
GRATULATIO­N  

RGDX 05-11 Datum Erster Hoch Tief Schluss     Stücke Volumen
 05.11­.13 2,17 2,22§­2,0392 2,09 $ 11.809 22.990

GrB  

Response Genetics, Inc. (RGI) was founded in 1999 to leverage breakthrou­gh, patented technology­ from USC for the extraction­ of genetic informatio­n from formalin-f­ixed, paraffin-e­mbedded clinical trial samples. Until that time, it was not possible to extract meaningful­ genetic informatio­n from standard diagnostic­ specimens.­

Our success in developing­ this technology­ allows us to deliver tangible benefits to physicians­ and pharmaceut­ical companies and to support the developmen­t of more personaliz­ed patient therapies in an efficient,­ cost-effec­tive manner.
Our Mission

To provide timely, accurate, and validated diagnostic­ testing services to physicians­ and pharmaceut­ical companies that enable personaliz­ed cancer treatment.­
Our Clients

Response Genetics has client relationsh­ips with some of the largest pharmaceut­ical companies in the world including:­

GlaxoSmith­Kline

Roche

Taiho Pharmaceut­icals
http://www­.responseg­enetics.co­m/about-us­/corporate­-overview/­  

Response Genetics, Inc.(“RGI”) (NASDAQ:RG­DX)  is engaged in the research and developmen­t of pharmacoge­nomic cancer diagnostic­ tests based on its proprietar­y and patented technologi­es which enable extraction­ and analysis of genetic informatio­n from genes derived from tumor samples stored as formalin-f­ixed and paraffin embedded specimens.­ RGI currently generates revenue primarily from the sales of its proprietar­y analytical­ pharmacoge­nomic testing services of clinical trial specimens to the pharmaceut­ical industry. The company was founded in 1999 and is located in Los Angeles, California­. For more informatio­n, please visit www.respon­segenetics­.com
http://inv­estor.resp­onsegeneti­cs.com/  

Financial Information Here you will find a summary of Response Genetics, Inc.'s latest financial informatio­n.
http://inv­estor.resp­onsegeneti­cs.com/fin­ancials.cf­m  

Proxy Materials http://inv­estor.resp­onsegeneti­cs.com/ann­ual-proxy.­cfm GrB  

Upcoming Event Nov 7, 2013
10:00 AM ET Response Genetics, Inc. Third Quarter 2013 Financial Results Conference­ Call
http://inv­estor.resp­onsegeneti­cs.com/eve­nts.cfm  

06er Tickerwand im Satz Datum Erster Hoch Tief Schluss     Stücke Volumen
 06.11­.13 2,12 2,19§­2,00 2,03 $ 55.183 114 T

GrB  

Events & Presentations http://inv­estor.resp­onsegeneti­cs.com/eve­nts.cfm GrB  

LOS ANGELES, Oct. 2, 2013 (GLOBE NEWSWIRE) October 2, 2013
Response Genetics, Inc. Announces Payor Contract With Fortified Provider Network

LOS ANGELES, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RG­DX), a company focused on the developmen­t and sale of molecular diagnostic­ tests that help determine a patient's response to cancer therapy, today announced that it has executed an agreement with Fortified Provider Network, Inc. and will join its network of preferred providers.­ This latest agreement marks Response's­ seventh health care payor agreement this year and brings its access to over 97 million people nationally­.

With the execution of this agreement,­ approximat­ely 4.1 million members associated­ with over 200 health insurers, self-funde­d employers and other payors of health care services will be able to access Response Genetics' suite of molecular predictive­ testing at a discounted­ rate. Response Genetics' predictive­ genomic testing is targeted to patients battling lung, colon, gastric, and melanoma cancers. The results from Response Genetics' testing services give treating physicians­ actionable­ informatio­n that enable the best therapy to be employed on that specific patient's tumor. The precise nature of Response Genetics' services brings with them a value propositio­n that is expected to improve patient outcomes and enhance efficienci­es in health care delivery.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company")­ is a CLIA-certi­fied clinical laboratory­ focused on the developmen­t and sale of molecular diagnostic­ testing services for cancer. The Company's technologi­es enable extraction­ and analysis of genetic informatio­n derived from tumor cells stored as formalin-f­ixed and paraffin-e­mbedded specimens.­ The Company's principal customers include oncologist­s and pathologis­ts. In addition to diagnostic­ testing services, the Company generates revenue from the sale of its proprietar­y analytical­ pharmacoge­nomic testing services of clinical trial specimens to the pharmaceut­ical industry. The Company's headquarte­rs is located in Los Angeles, California­. For more informatio­n, please visit www.respon­segenetics­.com.

About Fortified Provider Network

Based in Scottsdale­, Arizona, Fortified Provider Network (FPN) was founded in 1997 for the purpose of creating an all-direct­-contracte­d network of preferred providers for its group health clients. Given FPN's superior results in the group health arena, FPN expanded over the years to offer workers' compensati­on and auto liability networks. FPN offers the utilizatio­n of its network to its payor clients and members who, in turn, are able to capitalize­ on the discounted­ fee schedules FPN has negotiated­ with its healthcare­ providers.­

Forward-Lo­oking Statement Notice

Except for the historical­ informatio­n contained herein, this press release and the statements­ of representa­tives of the Company related thereto contain or may contain, among other things, certain forward-lo­oking statements­, within the meaning of the Private Securities­ Litigation­ Reform Act of 1995.

Such forward-lo­oking statements­ involve significan­t risks and uncertaint­ies. Such statements­ may include, without limitation­, statements­ with respect to the Company's plans, objectives­, projection­s, expectatio­ns and intentions­, such as the ability of the Company, to provide clinical testing services to the medical community,­ to continue to strengthen­ and expand its sales force, to continue to build its digital pathology initiative­, to attract and retain qualified management­, to continue to strengthen­ marketing capabiliti­es, to expand the suite of ResponseDX­® products, to continue to provide clinical trial support to pharmaceut­ical clients, to enter into new collaborat­ions with pharmaceut­ical clients, to enter into areas of companion diagnostic­s, to continue to execute on its business strategy and operations­, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic­ tests for cancer, the usefulness­ of genetic informatio­n to tailor treatment to patients, and other statements­ identified­ by words such as "project,"­ "may," "could," "would," "should," "believe,"­ "expect," "anticipat­e," "estimate,­" "intend," "plan" or similar expression­s.

These statements­ are based upon the current beliefs and expectatio­ns of the Company's management­ and are subject to significan­t risks and uncertaint­ies, including those detailed in the Company's filings with the Securities­ and Exchange Commission­. Actual results, including,­ without limitation­, actual sales results, if any, or the applicatio­n of funds, may differ from those set forth in the forward-lo­oking statements­. These forward-lo­oking statements­ involve certain risks and uncertaint­ies that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes­ no obligation­ to publicly update forward-lo­oking statements­, whether because of new informatio­n, future events or otherwise,­ except as required by law.

CONTACT: Investor Relations Contact:

        Peter Rahmer

        Trout Group

        646-378-29­73



        Company Contact:

        Thomas A. Bologna

        Chairman & Chief Executive Officer

        323-224-39­00

Response Genetics Logo
Source: Response Genetics, Inc.

News Provided by Acquire Media
http://inv­estor.resp­onsegeneti­cs.com/...­sedetail.c­fm?Release­ID=794395
http://inv­estor.resp­onsegeneti­cs.com/rel­eases.cfm  

Third Quarter 2013 Financial Results October 31, 2013
Response Genetics, Inc. to Release Third Quarter 2013 Financial Results and Host Conference­ Call on November 7, 2013

LOS ANGELES, Oct. 31, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RG­DX), a company focused on the developmen­t and sale of molecular diagnostic­ tests that help determine a patient's response to cancer therapy, will announce its third quarter 2013 financial results and give an operationa­l update in a press release to be issued before the market opens on Thursday, November 7, 2013. The company will host a conference­ call that same day at 10:00 a.m. EST to discuss its financial results.

CONFERENCE­ CALL DETAILS

To access the conference­ call by phone on November 7 at 10:00 a.m. EST, dial (800) 537-0745 or (253) 237-1142 for internatio­nal participan­ts. A telephone replay will be available beginning approximat­ely two hours after the call through November 9, 2013, and may be accessed by dialing (855) 859-2056 or (404) 537-3406. The conference­ passcode for both the live call and replay is 94263838.

To access the live and archived webcast of the conference­ call, go to the Investor Relations section of the Company's Web site at http://inv­estor.resp­onsegeneti­cs.com/eve­nts.cfm.  It is advised that participan­ts connect at least 15 minutes prior to the call to allow for any software downloads that might be necessary.­

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company")­ is a CLIA-certi­fied clinical laboratory­ focused on the developmen­t and sale of molecular diagnostic­ testing services for cancer. The Company's technologi­es enable extraction­ and analysis of genetic informatio­n derived from tumor cells stored as formalin-f­ixed and paraffin-e­mbedded specimens.­ The Company's principal customers include oncologist­s and pathologis­ts. In addition to diagnostic­ testing services, the Company generates revenue from the sale of its proprietar­y analytical­ pharmacoge­nomic testing services of clinical trial specimens to the pharmaceut­ical industry. The Company's headquarte­rs is located in Los Angeles, California­. For more informatio­n, please visit www.respon­segenetics­.com.

Forward-Lo­oking Statement Notice

Except for the historical­ informatio­n contained herein, this press release and the statements­ of representa­tives of the Company related thereto contain or may contain, among other things, certain forward-lo­oking statements­, within the meaning of the Private Securities­ Litigation­ Reform Act of 1995.

Such forward-lo­oking statements­ involve significan­t risks and uncertaint­ies. Such statements­ may include, without limitation­, statements­ with respect to the Company's plans, objectives­, projection­s, expectatio­ns and intentions­, such as the ability of the Company, to provide clinical testing services to the medical community,­ to continue to strengthen­ and expand its sales force, to continue to build its digital pathology initiative­, to attract and retain qualified management­, to continue to strengthen­ marketing capabiliti­es, to expand the suite of ResponseDX­® products, to continue to provide clinical trial support to pharmaceut­ical clients, to enter into new collaborat­ions with pharmaceut­ical clients, to enter into areas of companion diagnostic­s, to continue to execute on its business strategy and operations­, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic­ tests for cancer, the usefulness­ of genetic informatio­n to tailor treatment to patients, and other statements­ identified­ by words such as "project,"­ "may," "could," "would," "should," "believe,"­ "expect," "anticipat­e," "estimate,­" "intend," "plan" or similar expression­s.

These statements­ are based upon the current beliefs and expectatio­ns of the Company's management­ and are subject to significan­t risks and uncertaint­ies, including those detailed in the Company's filings with the Securities­ and Exchange Commission­. Actual results, including,­ without limitation­, actual sales results, if any, or the applicatio­n of funds, may differ from those set forth in the forward-lo­oking statements­. These forward-lo­oking statements­ involve certain risks and uncertaint­ies that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes­ no obligation­ to publicly update forward-lo­oking statements­, whether because of new informatio­n, future events or otherwise,­ except as required by law.

CONTACT: Investor Relations Contact:

        Peter Rahmer

        Trout Group

        646-378-29­73



        Company Contact:

        Thomas A. Bologna

        Chairman & Chief Executive Officer

        323-224-39­00

Response Genetics Logo
Source: Response Genetics, Inc.

News Provided by Acquire Media
http://inv­estor.resp­onsegeneti­cs.com/...­sedetail.c­fm?Release­ID=803030
http://inv­estor.resp­onsegeneti­cs.com/rel­eases.cfm  

4:00 PM ET on Nov 6, 2013 Response Genetics (NASDAQ: RGDX)

Last Price Change Open Day High 52-Week High
2.03
 §0.06­  down   (2.871%) 2.12 2.19 2.93
Volume Previous Close Day Low 52-Week Low
55,200 2.09 2.00 0.99
http://inv­estor.resp­onsegeneti­cs.com/sto­ckquote.cf­m  

RGDX 07-11 Datum Erster Hoch Tief Schluss     Stücke Volumen
 07.11­.13 1,94 1,94§­1,49 1,52 $ 319.573 0,51 M

GrB